Drug Makers Ask JPML to Create Federal Docket in N.Y. for Eliquis Actions

WASHINGTON, D.C. — The makers of Eliquis (apixaban) have asked the Judicial Panel on Multidistrict Litigation to create a federal docket for actions involving the anticoagulant drug in the U.S. District Court for the Southern District of New York, arguing that coordination will serve the convenience of the parties and promote the just and efficient conduct of the actions.

In an Oct. 13 motion, Bristol-Myers Squibb Co. and Pfizer Inc. argued that the 34 pending Eliquis actions involve similar products liability claims, all of which arise from the design, testing, regulatory approval, manufacture, and marketing of the drug, thus presenting …